

PERSONAL INFORMATION **Edward Laane**

WORK EXPERIENCE

- September 1997-August 2001 **Resident of Hematology**
Tartu University (Estonia)
Training in Hematology
- April 2002-September 2006 **PhD student**
Karolinska Institutet (Sweden)
Research in experimental oncology and pathology
- September 2001-November 2011 **PhD student**
Tartu University (Estonia)
Research in hematology
- September 2006-December 2007 **Hematologist**
North Estonia Regional Hospital (Estonia)
Physician
- January 2008-June 2010 **Head of Department of Hematology**
North Estonia Regional Hospital (Estonia)
Administrative
- July 2010-December 2012 **Head of Center of Hematology**
North Estonia Medical Center (Estonia)
Administrative
- March 2008-January 2016 **Assistant**
Tartu University (Estonia)
Teaching
- January 2013-December 2017 **Senior Consultant Haematologist lecturer**
North Estonia Regional Hospital (Estonia)
Physician and teaching
- January 2015-December 2015 **Research Scholar**
Dana-Farber Cancer Institute (United States)
Genomic instability studies in multiple myeloma
- February 2016- Present **Associate professor of Hematology**
Tartu University (Estonia)
Teaching, research and administrative
- May 2018- Present **Member of the Board**
Kuressaare Hospital (Estonia)
Administrative and Physician, Head Doctor

EDUCATION AND TRAINING

- September 1990-June 1996 **Physician**
Tartu University (Estonia)
- September 1996-June 1997 **Internship**
Tartu University (Estonia)

Expertise Multiple myeloma
 Lymphomas
 Leukemias
 Myelodysplastic syndromes
 Myeloproliferative neoplasms
 Haemophilia
 Anemias
 Neutropenias

- Publications**
- 1) Pikta M, Banys V, Szanto T, Joutsu-Korhonen L, Vaide I, Varik M, Lehtinen AE, Giangrande P, Laane E. Von Willebrand Factor Multimeric Assay in Acquired von Willebrand Disease Diagnosis: A Report of Experience from North Estonia Medical Centre. *J Lab Physicians*. 2021 Sep;13(3):195-201. doi: 10.1055/s-0041-1730818. Epub 2021 Jun 28.
 - 2) Mapping the human genetic architecture of COVID-19. COVID-19 Host Genetics Initiative. *Nature*. 2021 Dec;600(7889):472-477. doi: 10.1038/s41586-021-03767-x. Epub 2021 Jul 8.
 - 3) Yu JK, Iorio A, Edginton AN; WAPPS co-investigators. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. *Res Pract Thromb Haemost*. 2019 May 20;3(3):528-541. doi: 10.1002/rth2.12204. eCollection 2019 Jul.
 - 4) Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Duran MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Peceliunas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbenyi Z, Abadi U, Pedersen RS, Cernelc P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. *Clin Lymphoma Myeloma Leuk*. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25.
 - 5) Tzogani K, van Hennik P, Walsh I, De Graeff P, Folin A, Sjöberg J, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. *Oncologist*. 2018 May;23(5):631-636. doi: 10.1634/theoncologist.2017-0301. Epub 2017 Nov 30. Erratum in: *Oncologist*. 2018 Jul;23(7):870.
 - 6) Tzogani K, Camarero Jimenez J, Garcia I, Sancho-Lopez A, Martin M, Moreau A, Demolis P, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. *Oncologist*. 2017 Nov;22(11):1339-1346. doi: 10.1634/theoncologist.2017-0184. Epub 2017 Sep 21.
 - 7) D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastiris E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWW- 8 consensus panel. *Br J Haematol*. 2017 Mar;176(5):728-742. doi: 10.1111/bjh.14492. Epub 2017 Feb 15.
 - 8) Berntorp E, Dargaud Y, Hart D, Lobet S, Mancuso ME, d'Oiron R, Perry D, Pollard D, van den Berg M, Blatny J, Chambost H, Doria AS, Holme PA, Kaczmarek R, Mantovani L, McLaughlin P, Nanayakkara L, Petrini P, Sannie T, Laane E, Maia R, Dettoraki A, Farrell A, Halimeh S, Raza S, Taylor S. The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany. *Eur J Haematol*. 2017 Jan;98 Suppl 85:1-15. doi: 10.1111/ejh.12828.
 - 9) Hulegardh E, Punab M, Holmberg E, Palk K, Laane E, Everaus H, Wennstrom L, Stockelberg D. Acute de novo Leukemia in Estonia and Western Sweden 1982-2006: Positive Trend in the Survival of Acute Leukemia over 25 Years. *Acta Haematol*. 2016;136(3):167-73. doi: 10.1159/000446525.
 - 10) Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. *Oncologist*. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276.
 - 11) Bron D, Ades L, Fulop T, Goede V, Stauder R; Elderly Task Force in Hematology EHA SWG.. Aging and blood disorders: new perspectives, new challenges. *Haematologica*. 2015

Apr;100(4):415-7. doi: 10.3324/haematol.2015.126771.

12) Hanaizi Z, Flores B, Hemmings R, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist*. 2015 Mar;20(3):329-34. doi: 10.1634/theoncologist.2014-0073. Review.

13) Derolf AR, Laane E, Bjorklund E, Saft L, Bjorkholm M, Porwit A. Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia. *Scand J Immunol*. 2014 Dec;80(6):424-31. doi: 10.1111/sji.12223.

14) Hanaizi Z, Unkrig C, Enzmann H, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist*. 2014 Apr;19(4):421-5. doi: 10.1634/theoncologist.2013-0294. Epub 2014 Mar 25.

15) Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Gulbrandsen N, Haukas E, Carlson K, Kvam AK, Nahi H, Lindas R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. *Blood*. 2013 Jun 6;121(23):4647-54. doi: 10.1182/blood-2012-11-464503. Epub 2013 Apr 24.

16) Pean E, Flores B, Hudson I, Sjoberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. The European Medicines Agency Review of Pixantrone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. *Oncologist*. 2013;18(5):625-33. doi: 10.1634/theoncologist.2013-0020. Epub 2013 Apr 24.

17) Punab M, Palk K, Varik M, Laane E, Everaus H, Holmberg E, Hulegardh E, Wennstrom L, Safai-Kutti S, Stockelberg D, Kutti J. Sequential population-based studies over 25 years on the incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1982-2006: a survey of patients aged 65 years. *Med Oncol*. 2013 Mar;30(1):487. doi: 10.1007/s12032-013-0487-x. Epub 2013 Feb 9.

18) Kharaziha P, De Raeve H, Fristedt C, Li Q, Gruber A, Johnsson P, Kokaraki G, Panzar M, Laane E, Osterborg A, Zhivotovsky B, Jernberg-Wiklund H, Grander D, Celsing F, Bjorkholm M, Vanderkerken K, Panaretakis T. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. *Cancer Res*. 2012 Oct 15;72(20):5348-62. doi: 10.1158/0008-5472.CAN-12-0658. Epub 2012 Sep 4.

19) Buentke E, Nordstrom A, Lin H, Bjorklund AC, Laane E, Harada M, Lu L, Tegnebratt T, Stone-Elander S, Heyman M, Soderhall S, Porwit A, Ostenson CG, Shoshan M, Tamm KP, Grander D. Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells. *Blood Cancer J*. 2011 Jul;1(7):e31. doi: 10.1038/bcj.2011.27. Epub 2011 Jul 29.

20) Grander D, Kharaziha P, Laane E, Pokrovskaja K, Panaretakis T. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. *Autophagy*. 2009 Nov;5(8):1198-200. Epub 2009 Nov 18.

21) Laane E, Tamm KP, Buentke E, Ito K, Kharaziha P, Oscarsson J, Corcoran M, Bjorklund AC, Hultenby K, Lundin J, Heyman M, Soderhall S, Mazur J, Porwit A, Pandolfi PP, Zhivotovsky B, Panaretakis T, Grander D. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. *Cell Death Differ*. 2009 Jul;16(7):1018-29. doi: 10.1038/cdd.2009.46. Epub 2009 Apr 24. Erratum in: *Cell Death Differ*. 2009 Jul;16(7):1071. Khahariza, P [corrected to Kharaziha, P].

22) Laane E, Panaretakis T, Pokrovskaja K, Buentke E, Corcoran M, Soderhall S, Heyman M, Mazur J, Zhivotovsky B, Porwit A, Grander D. Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. *Haematologica*. 2007 Nov;92(11):1460-9.

23) Laane E, Bjorklund E, Mazur J, Lonnerholm G, Soderhall S, Porwit A. Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia. *Scand J Immunol*. 2007 Nov;66(5):572-83. Epub 2007 Sep 24.

24) Laane E, Derolf AR, Bjorklund E, Mazur J, Everaus H, Soderhall S, Bjorkholm M, Porwit-MacDonald A. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. *Haematologica*. 2006 Jun;91(6):833-6.

25) Panaretakis T, Laane E, Pokrovskaja K, Bjorklund AC, Moustakas A, Zhivotovsky B, Heyman M, Shoshan MC, Grander D. Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. *Mol Biol Cell*. 2005 Aug;16(8):3821-31. Epub 2005 May 25.

26) Laane E, Tani E, Bjorklund E, Elmberger G, Everaus H, Skoog L, Porwit-MacDonald A. Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma. *Cytometry B Clin Cytom*. 2005 Mar;64(1):34-42.

Projects World Federation of Hemophilia, Hemophilia Treatment Centre Twinning Project, 2014-2017, Tallinn (Estonia) - Helsinki (Finland)

Memberships Past President of the Estonian Society of Hematology 2010-2013
Member of European Hematology Association
European Hematology Association Scientific Working on Group Quality of Life and Symptoms, Chair
Member of the Japanese Society of Hematology
Member of Nordic Myeloma Study Group
Member of Nordic Chronic Myeloid Leukemia Study Group
Member of Nordic Lymphoma Study Group

Other Relevant Information